Cover Image
市場調查報告書

Actavis plc的產品平台分析

Actavis plc - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321943
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
Actavis plc的產品平台分析 Actavis plc - Product Pipeline Review - 2015
出版日期: 2015年05月20日 內容資訊: 英文 101 Pages
簡介

Actavis plc 是總公同位於愛爾蘭的製藥企業,從事品牌醫藥品,非專利,生技仿製藥產品的開發,製造,銷售。2012年Watson 收買了pharmaceuticals之後,該公司以在全球60個國家以上擴展業務的全球第三大製藥企業身份,提供中樞神經系統、泌尿系統、女性醫療、荷爾蒙、腫瘤、心血管系統、腎臟系、消化器官系統等領域的產品。

本報告提供Actavis plc 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Actavis plc 基本資料

  • Actavis plc 概要
  • 主要資訊
  • 企業資料

Actavis plc :R&D概要

  • 主要的治療範圍

Actavis plc :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Actavis plc :開發中產品概況

  • 後期階段產品開發中產品
    • 登記前的產品/聯合治療模式
    • 申請被不受理了的/被撤消了的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA Filed Products/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Actavis plc :藥物簡介

  • (ceftazidime + avibactam)
  • (memantine hydrochloride ER + donepezil hydrochloride)
  • APT-1026
  • dalbavancin
  • (nebivolol + valsartan)
  • cariprazine
  • norethindrone
  • (aclidinium bromide + formoterol fumarate)
  • estradiol acetate
  • follitropin alfa
  • pancrelipase DR
  • udenafil
  • ulipristal acetate
  • WC-2055
  • (ceftaroline fosamil + avibactam)
  • (estrogen + progesterone)
  • albaconazole
  • cebranopadol
  • memantine hydrochloride
  • oxybutynin hydrochloride
  • sarecycline
  • EUR-1100
  • Progesterone Vaginal Gel Second Generation
  • bezafibrate ER

Actavis plc :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Actavis plc :最新的開發平台資訊

Actavis plc :開發暫停中的計劃

Actavis plc :開發中止的產品

Actavis plc :企業理念

Actavis plc :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07051CDB

Summary

Global Markets Direct's, 'Actavis plc - Product Pipeline Review - 2015', provides an overview of the Actavis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Actavis plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Actavis plc's pipeline products

Reasons to buy

  • Evaluate Actavis plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Actavis plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Actavis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actavis plc Snapshot
    • Actavis plc Overview
    • Key Information
    • Key Facts
  • Actavis plc - Research and Development Overview
      Key Therapeutic Areas
  • Actavis plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Actavis plc - Pipeline Products Glance
    • Actavis plc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Actavis plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actavis plc - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Actavis plc - Drug Profiles
    • APT-1026
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cariprazine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • norethindrone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (aclidinium bromide + formoterol fumarate)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftazidime + avibactam sodium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimatoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dalbavancin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • follitropin alfa (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pancrelipase DR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarecycline hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ulipristal acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WC-3011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (ceftaroline fosamil + avibactam sodium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • memantine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxybutynin chloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EUR-1100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGN-232411
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Progesterone Second Generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bezafibrate ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actavis plc - Pipeline Analysis
    • Actavis plc - Pipeline Products by Target
    • Actavis plc - Pipeline Products by Route of Administration
    • Actavis plc - Pipeline Products by Molecule Type
    • Actavis plc - Pipeline Products by Mechanism of Action
  • Actavis plc - Recent Pipeline Updates
  • Actavis plc - Dormant Projects
  • Actavis plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alvameline maleate
      • dexamethasone
      • dexloxiglumide
      • ME-1036
      • neramexane mesylate
      • oglemilast
      • onabotulinumtoxin A
      • radiprodil
  • Actavis plc - Company Statement
  • Actavis plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actavis plc, Key Information
  • Actavis plc, Key Facts
  • Actavis plc - Pipeline by Indication, 2015
  • Actavis plc - Pipeline by Stage of Development, 2015
  • Actavis plc - Monotherapy Products in Pipeline, 2015
  • Actavis plc - Combination Treatment Modalities in Pipeline, 2015
  • Actavis plc - Partnered Products in Pipeline, 2015
  • Actavis plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Actavis plc - Pre-Registration, 2015
  • Actavis plc - Filing rejected/Withdrawn, 2015
  • Actavis plc - Phase III, 2015
  • Actavis plc - Phase II, 2015
  • Actavis plc - Phase I, 2015
  • Actavis plc - IND/CTA Filed, 2015
  • Actavis plc - Discovery, 2015
  • Actavis plc - Pipeline by Target, 2015
  • Actavis plc - Pipeline by Route of Administration, 2015
  • Actavis plc - Pipeline by Molecule Type, 2015
  • Actavis plc - Pipeline Products by Mechanism of Action, 2015
  • Actavis plc - Recent Pipeline Updates, 2015
  • Actavis plc - Dormant Developmental Projects,2015
  • Actavis plc - Discontinued Pipeline Products, 2015
  • Actavis plc, Subsidiaries

List of Figures

  • Actavis plc - Pipeline by Top 10 Indication, 2015
  • Actavis plc - Pipeline by Stage of Development, 2015
  • Actavis plc - Monotherapy Products in Pipeline, 2015
  • Actavis plc - Combination Treatment Modalities in Pipeline, 2015
  • Actavis plc - Partnered Products in Pipeline, 2015
  • Actavis plc - Pipeline by Top 10 Target, 2015
  • Actavis plc - Pipeline by Top 10 Route of Administration, 2015
  • Actavis plc - Pipeline by Top 10 Molecule Type, 2015
  • Actavis plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top